Pharma major Mylan gets go-ahead to make remdesivir for 'restricted emergency use'

Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted. On June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2YQrOwk
via IFTTT